Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 sept. 2020 07h30 HE | Source: Ocugen

Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

MALVERN, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
08 sept. 2020 16h25 HE | Source: Ocugen

Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing...
03 sept. 2020 07h30 HE | Source: Ocugen

Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

MALVERN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
28 août 2020 07h40 HE | Source: Ocugen

Ocugen to Present at the LD 500 Virtual Investor Conference

MALVERN, Pa., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
14 août 2020 07h30 HE | Source: Ocugen

Ocugen Provides Business Update and Second Quarter 2020 Financial Results

Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Ocugen,...
10 août 2020 07h30 HE | Source: Ocugen

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
06 août 2020 13h45 HE | Source: Ocugen

Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

MALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
27 juil. 2020 07h30 HE | Source: Ocugen

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
21 juil. 2020 17h15 HE | Source: Ocugen

Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat...
03 juin 2020 08h30 HE | Source: Ocugen

Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

MALVERN, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...

Page précédente